Machine Learning Used to Develop Drugs for Alzheimer's Disease

AZoRobotics speaks with Alice Ruixue Ai from the University of Oslo about her efforts to create an artificial intelligence (AI)-based virtual screening algorithm and a cross-species Alzheimer's disease (AD) drug verification system. This system could help provide a fast, cost-effective and highly accurate method for the identification of potent mitophagy inducers to maintain brain health. Alzheimer's Disease (AD) is the most common form of dementia, seen mainly in the elderly. Around 50 million people in the world suffer from dementia, and about 70% of those people have AD, so this is a huge problem for society. It is estimated that managing the health and social costs for people with AD will cost about 2 trillion dollars by the year 2030.